Payment overview · 2025
General Payments
$800.42
49 reported records · 12 companies
Healthcare provider profile · identity verified
Travis B Henderson, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MOBRIDGE, SD · NPI 1558343061
Verified facts
What the public records show
CMS Open Payments records show Travis B Henderson, MD received $800.42 in general payments during 2025 across 49 reported records.
Lilly USA, LLC accounted for 26.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Myrbetriq by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 241 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $208.50 | 26.1% | 12 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $205.77 | 25.7% | 14 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $90.55 | 11.3% | 5 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $77.27 | 9.7% | 6 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $65.18 | 8.1% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $49.22 | 6.2% | 3 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $22.84 | 2.9% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.76 | 2.3% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $16.54 | 2.1% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $16.26 | 2.0% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$15.01 | 1.9% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $14.52 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $800.42 | 49 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $177.78 | 12 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $177.78 | 12 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $172.50 | 10 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $77.27 | 6 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $75.68 | 4 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $65.18 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $57.66 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $54.76 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $49.22 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $49.22 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $27.99 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $27.99 | 2 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $22.84 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $16.54 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $16.26 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $16.26 | 1 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $15.01 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.87 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $14.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 142 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 120 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
142 | 24 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
241 | 36 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
142 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
120 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 387 | 75 |
| Metoprolol Succinate | Metoprolol Succinate | 372 | 70 |
| Levothyroxine Sodium | Levothyroxine Sodium | 362 | 56 |
| Losartan Potassium | Losartan Potassium | 273 | 55 |
| Eliquis | Apixaban | 241 | 36 |
| Furosemide | Furosemide | 226 | 50 |
| Amlodipine Besylate | Amlodipine Besylate | 215 | 41 |
| Lisinopril | Lisinopril | 211 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 206 | 34 |
| Spironolactone | Spironolactone | 154 | 30 |
| Gabapentin | Gabapentin | 152 | 24 |
| Omeprazole | Omeprazole | 150 | 40 |
| Simvastatin | Simvastatin | 150 | 37 |
| Jardiance | Empagliflozin | 142 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 129 | 27 |
| Ozempic | Semaglutide | 120 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 118 | 23 |
| Famotidine | Famotidine | 114 | 17 |
| Donepezil Hcl | Donepezil Hcl | 99 | 17 |
| Atenolol | Atenolol | 86 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 86 | 25 |
| Clonazepam | Clonazepam | 84 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 83 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 81 | 22 |
| Farxiga | Dapagliflozin Propanediol | 77 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 76 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 76 | 22 |
| Finasteride | Finasteride | 73 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 73 | 15 |
| Xarelto | Rivaroxaban | 73 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 72 | 18 |
| Paroxetine Hcl | Paroxetine Hcl | 72 | 13 |
| Midodrine Hcl | Midodrine Hcl | 70 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 67 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 63 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 63 | 13 |
| Divalproex Sodium | Divalproex Sodium | 62 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 61 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 60 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 60 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 53 | suppressed |
| Potassium Chloride | Potassium Chloride | 51 | 15 |
| Synthroid | Levothyroxine Sodium | 49 | suppressed |
| Allopurinol | Allopurinol | 48 | 11 |
| Ondansetron Odt | Ondansetron | 48 | 19 |
| Montelukast Sodium | Montelukast Sodium | 47 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 46 | suppressed |
| Memantine Hcl | Memantine Hcl | 45 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 45 | suppressed |
| Trulicity | Dulaglutide | 44 | suppressed |
| Mirtazapine | Mirtazapine | 43 | suppressed |
| Pregabalin | Pregabalin | 43 | suppressed |
| Prednisone | Prednisone | 39 | 16 |
| Loperamide | Loperamide Hcl | 38 | suppressed |
| Alprazolam | Alprazolam | 37 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 35 | suppressed |
| Entresto | Sacubitril/Valsartan | 33 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 32 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | suppressed |
| Zaleplon | Zaleplon | 32 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 31 | 31 |
| Trazodone Hcl | Trazodone Hcl | 31 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 31 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 29 | 15 |
| Diltiazem 24hr Er | Diltiazem Hcl | 29 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 29 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 29 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 28 | suppressed |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 27 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Myrbetriq | Mirabegron | 26 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 26 | 20 |
| Bupropion Hcl Sr | Bupropion Hcl | 25 | suppressed |
| Digoxin | Digoxin | 25 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Metformin Hcl | Metformin Hcl | 25 | suppressed |
| Methotrexate | Methotrexate Sodium | 24 | suppressed |
| Trospium Chloride | Trospium Chloride | 24 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 23 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 22 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 22 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 21 | suppressed |
| Linzess | Linaclotide | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Lubiprostone | Lubiprostone | 19 | suppressed |
| Tradjenta | Linagliptin | 19 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Mounjaro | Tirzepatide | 18 | suppressed |
| Carvedilol | Carvedilol | 17 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 17 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 16 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 16 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Ezetimibe | Ezetimibe | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 13 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 12 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 12 | suppressed |
| Mesalamine Er | Mesalamine | 12 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 11 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $800.42 · 49 records | Lilly USA, LLC | CAMZYOS, Cologuard Collection Kit, EVENITY, JARDIANCE, JOURNAVX, LEQVIO, MINIMED 780G, MOUNJARO, OPSUMIT, OTEZLA, Ozempic, PROLIA, REPATHA, Rybelsus, The Cologuard Plus Collection Kit, UPTRAVI, VOQUEZNA, Veozah, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error